APSR2026-881

 
Late-Breaking
Submitted
Oral Presentation
YIA02-002
 
 
https://storage.unitedwebnetwork.com/files/1285/1207560-46903-ASPR presentation 2026_433956.pptx
Format: PPTX Only
 
Format: PDF Only
08. Lung Cancer
3

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Sai Fung Yeung * The Chinese University of Hong Kong School of Biomedical Science Hong Kong Hong Kong
Tsz Yiu Law - The Chinese University of Hong Kong School of Biomedical Science Hong Kong Hong Kong
Kwok Wing Tsui - The Chinese University of Hong Kong School of Biomedical Science Hong Kong Hong Kong
 
 
 
 
 
 
 
 
 
 
 
 
Presenting Author Details
Sai Fung
Yeung
sfrk.yeung@cuhk.edu.hk
+85266772941
31-40
 
Original Research
TRiC complex coordinates proteostasis and lipid metabolism to drive targeted therapy resistance in lung cancer
Maximum 25 words
Abstract Content
Acquired resistance limits the durability of targeted therapies in non-small cell lung cancer (NSCLC). To survive therapeutic stress, resistant tumour cells must adapt both proteostasis and metabolic programs. We investigated the role of the TRiC chaperonin complex in coordinating these adaptive processes, with particular focus on its integration of protein homeostasis and lipid metabolism, and evaluated whether this axis could be therapeutically exploited to enhance the efficacy of targeted therapies.
Clinical relevance was assessed using public transcriptomic datasets and lung cancer tissue microarrays. TRiC function was perturbed by silencing CCT2 and additional TRiC components in targeted therapy-sensitive and -resistant NSCLC models. Cell proliferation, invasion, apoptosis, and drug sensitivity were evaluated in vitro. Mechanistic studies included RNA sequencing, antibody array profiling, targeted lipidomics, and single-cell analysis to define tumour-state changes associated with TRiC disruption and therapeutic resistance. High-throughput virtual screening was performed to identify a candidate small-molecule TRiC-targeting compound, which was further evaluated in vitro and in orthotopic resistant lung tumour models.
TRiC pathway activation was associated with poor outcome, promoted malignant growth, and drug tolerance in NSCLC models. TRiC disruption suppressed proliferation and invasion, increased apoptosis, and enhanced sensitivity to KRAS- and EGFR-targeted therapies. Multi-omic analyses showed pronounced lipid metabolic remodeling, including reduced lipid species and acylcarnitines, consistent with impaired fatty acid utilization under drug stress. Resistant models showed overlapping lipidomic changes after CCT2 knockdown and broader TRiC disruption, supporting a central role for TRiC in metabolic fitness. Antibody array profiling identified enhanced IGF1R signaling across multiple drug-resistant states, while single-cell analysis supported tumour-state heterogeneity linked to this adaptive program. These data support an IGF1R-mTOR-TRiC axis that coordinates proteostasis and lipid metabolism in resistant cells. In an orthotopic sotorasib-resistant relapsed mKRC.1 model, an HTVS-identified compound induced regression of sotorasib-resistant lung tumours.
The TRiC complex is a key adaptive node linking proteostasis and lipid metabolic rewiring during targeted therapy resistance in NSCLC. Targeting this dependency represents a promising strategy to overcome resistance and improve the efficacy of current targeted therapies.
 
 
 
 
 
Yes
Yes
https://storage.unitedwebnetwork.com/files/1285/1207560-37089-poster_381939.jpg
JPG or JPEG or PNG format ONLY
proteostasis, lipid metabolism, lung cancer
maximum 3 keywords and no abbreviations, separated by commas
This research is funded by the Research Impact Fund (Ref. No.:R4015‐19) from the Research Grants Council in Hong Kong. Reference: (1) Genes & Diseases, 2025,101795,ISSN 2352-3042, https://doi.org/10.1016/j.gendis.2025.101795. (2) Front Genet . 2020 Mar 19:11:172. doi: 10.3389/fgene.2020.00172. (3) Biochem Pharmacol . 2025 Dec;242(Pt 2):117333. doi: 10.1016/j.bcp.2025.117333.
330